Berry Global has announced that it will construct a new facility in Bangalore, India that will serve as an R&D center and will add manufacturing capacity for devices, including nasal spray pumps and inhalers, to meet demand in South Asia. Berry already has one manufacturing facility in Bangalore.
Berry Global Chairman and CEO Tom Salmon commented, “Investing in our global healthcare business in Bangalore is a significant step in supporting our pharmaceutical, over-the-counter, and medical device customers aligned to forecasted market needs. During the pandemic, we’ve learned that strategically placed facilities across the world provide efficient localized support for customers of any size. We believe this investment significantly benefits the India and South Asia patient populations.”
Read the Berry Global press release.
